Skip to content
DataLookout
Menu

CURE-IBS-DNCT07238790

Use of A Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With Diarrhea

StatusRecruiting
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 5 more changesShow less
    • Eligibility criteria shortened, about 44 words
    • Start date changed from estimate of Dec 2025 to Mar 10, 2026
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description shortened, about 8 words
    • Site details revised at 2 of 2 sites
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Determine the safety of MITI-001 in the participant population
Timeframe: up to 90 days

Secondary (2)

Assess the ability of MITI-001 to restore microbial metabolic function: secondary bile acid metabolism and hydrogen consumption
Adequate relief of IBS-D symptoms

Arms and interventions

Intervention arm (MITI-001)Experimental

Dosed with MITI-001

Drugs: MITI-001 administration

Sites

2 sites in 1 country